Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies

Inclusion Criteria

• •1. Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses.
• •2. Aged at least 18 years.
• •3. Module A: Patient must have a documented activating alteration of the RAS-MAPK pathway.
• •4. Module B: Dose Escalation Phase: Patient must have a documented activating alteration of the RAS-MAPK pathway; Dose Expansion Phase: Expansion cohorts will be further defined based on information from the Dose Escalation.
• •5. Histological or cytological confirmation of a solid tumour.
• •6. Patient with solid tumors must have at least 1 lesion, not previously irradiated.
• •7. Estimated life expectancy of minimum of 12 weeks.
• •8. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
• •9. Ability to swallow and retain oral medication.